Lisinopril FAERS Safety Signals: What Post-Market Surveillance Data Reveals

What FAERS Is and Why It Matters for Lisinopril

The FDA Adverse Event Reporting System (FAERS) collects voluntary reports of suspected medication side effects from healthcare professionals, patients, and manufacturers. It is not a controlled trial. It is a real-world signal detection tool that has shaped drug safety decisions for decades 1.

Lisinopril occupies a distinctive position in FAERS because of its prescribing volume. With roughly 90 million prescriptions dispensed annually in the United States, it consistently ranks among the top 5 most-prescribed medications nationwide 2. That volume translates into a massive adverse-event dataset. By Q1 2025, FAERS contained over 90,000 cumulative case reports listing lisinopril as the primary or secondary suspect drug. The sheer size of this dataset makes disproportionality analysis (the statistical method FAERS uses to flag safety signals) particularly informative for this drug.

A FAERS "signal" does not confirm causation. The system identifies reporting rate imbalances using metrics like the proportional reporting ratio (PRR) and the empirical Bayesian geometric mean (EBGM). When a specific adverse event appears more frequently with lisinopril than expected across the full database, it triggers a signal for FDA review 3.

Angioedema: The Most Clinically Urgent Signal

Angioedema is the safety signal that has generated the most FDA attention and the most label changes for lisinopril. ACE inhibitors as a class inhibit bradykinin degradation, which can trigger rapid subcutaneous or submucosal swelling of the face, tongue, glottis, and larynx 4.

The reported incidence across clinical trials ranges from 0.1% to 0.7%. That range understates the racial disparity. A 2008 pharmacovigilance analysis of FAERS data found that Black patients were 3 to 4 times more likely to report angioedema with ACE inhibitors compared to White patients 4. The ALLHAT trial (N=33,357) confirmed this pattern: among the 9,054 participants randomized to lisinopril, angioedema occurred at a rate of 0.4% overall but disproportionately in Black participants 5.

Dr. Jackson Wright, a principal investigator on ALLHAT, noted: "The angioedema risk with ACE inhibitors in African Americans is not trivial and should factor into first-line antihypertensive selection for this population" 5.

FAERS data between 2004 and 2023 show angioedema as the adverse event with the highest EBGM score for lisinopril, exceeding the signal threshold by a wide margin. Reports frequently describe onset within the first 30 days of therapy, though late-onset cases (after years of stable use) appear in the database and have prompted FDA communications warning clinicians that angioedema can emerge at any point during treatment 6.

The current FDA label carries a prominent warning: angioedema involving the tongue, glottis, or larynx may cause airway obstruction and can be fatal. Patients experiencing any facial or throat swelling must discontinue lisinopril immediately and seek emergency care 6.

Cough: The Most Common Reason for Discontinuation

Dry, nonproductive cough is the adverse event most frequently reported with lisinopril in both FAERS and clinical practice. The mechanism is the same bradykinin accumulation responsible for angioedema, but the clinical expression is far milder and far more common 7.

Reported incidence varies by study design. Controlled trials estimate 5 to 12% of patients develop cough. Observational studies suggest the true prevalence may be higher because patients often tolerate symptoms for months before reporting them. Women are affected roughly twice as often as men. East Asian populations show higher susceptibility, with some Japanese and Chinese cohort studies reporting cough rates above 15% 7.

FAERS cough reports for lisinopril consistently rank in the top 3 by volume among all ACE inhibitor listings. The PRR for cough with lisinopril exceeds that of most other antihypertensive classes, confirming it as a class-specific signal rather than background noise.

Cough typically resolves within 1 to 4 weeks after discontinuation. The 2017 ACC/AHA Hypertension Guideline recommends switching to an angiotensin receptor blocker (ARB) when ACE inhibitor cough becomes intolerable, noting that ARBs do not share this bradykinin-mediated effect 8.

Hyperkalemia: A Signal Amplified by Polypharmacy

Lisinopril reduces aldosterone secretion, which decreases renal potassium excretion. In isolation, this effect is usually modest. The FAERS signal for hyperkalemia becomes clinically significant in specific drug combinations 9.

The FDA label warns against concurrent use of lisinopril with potassium-sparing diuretics (spironolactone, eplerenone, amiloride), potassium supplements, or potassium-containing salt substitutes without close monitoring 6. FAERS data reinforce this: a disproportionate number of hyperkalemia reports involve co-prescribed spironolactone or trimethoprim. A 2004 population-based study in Ontario found that after the RALES trial popularized adding spironolactone to ACE inhibitors for heart failure, hyperkalemia-related hospitalizations increased 4-fold and associated mortality rose significantly 9.

Risk factors identified across FAERS reports include:

• Estimated GFR below 30 mL/min/1.73 m²
• Age over 65
• Diabetes mellitus (especially with diabetic nephropathy)
• Concurrent NSAID use
• Volume depletion from any cause

The 2024 KDIGO guideline for CKD management recommends checking serum potassium within 1 to 2 weeks of starting or uptitrating any RAS inhibitor, including lisinopril, and repeating after any dose change or addition of interacting medications 10.

Acute Kidney Injury and Renal Deterioration

ACE inhibitors dilate the efferent glomerular arteriole, reducing intraglomerular pressure. This is kidney-protective over the long term but can precipitate acute kidney injury (AKI) when renal perfusion is already compromised 11.

FAERS reports of AKI with lisinopril cluster around three clinical scenarios: volume depletion (from diuretics, vomiting, diarrhea, or poor oral intake), bilateral renal artery stenosis, and concurrent NSAID use. The "triple whammy" combination of ACE inhibitor plus diuretic plus NSAID appears repeatedly in serious AKI reports and carries a PRR substantially above baseline in the FAERS database 12.

A 2014 BMJ study (N=487,372) quantified this interaction: patients taking all three drug classes simultaneously had a 31% higher risk of AKI hospitalization within the first 30 days compared to patients on a single agent alone 12.

The FDA label for lisinopril states: "In patients with severe congestive heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death" 6.

Baseline serum creatinine and a repeat measurement within 1 to 2 weeks of initiation remain standard practice. A rise exceeding 30% from baseline warrants reevaluation of the drug and the patient's volume status.

Fetal Toxicity: The Boxed Warning

Lisinopril carries a boxed warning (the FDA's most serious label category) for fetal toxicity. Use during the second and third trimesters has been associated with fetal renal failure, oligohydramnios, skull hypoplasia, and neonatal death 6.

FAERS fetal-exposure reports, though lower in volume than cough or angioedema reports, carry high severity scores. The mechanism is straightforward: the fetal kidney depends on an intact renin-angiotensin system for normal development, and ACE inhibition disrupts this pathway.

The 2017 ACC/AHA guideline is explicit: "ACE inhibitors and ARBs should not be used in pregnancy and should be discontinued as soon as pregnancy is detected" 8. First-trimester exposure data are less definitive, but a 2006 NEJM study (N=29,507 infants) found a 2.7-fold increased risk of major congenital malformations with first-trimester ACE inhibitor exposure compared to no antihypertensive use 13.

Women of reproductive potential starting lisinopril should receive counseling about contraception. Pregnancy testing before initiation is recommended in guidelines from ACOG 14.

Hypotension: First-Dose and Volume-Related Events

First-dose hypotension is a recognized ACE inhibitor class effect. FAERS reports of symptomatic hypotension with lisinopril are most concentrated in patients with activated renin-angiotensin systems: those on high-dose diuretics, those on sodium-restricted diets, those with heart failure (NYHA III or IV), and dialysis patients 6.

The FDA label recommends starting lisinopril at 5 mg (or 2.5 mg in heart failure patients) and reducing or temporarily withholding concomitant diuretics before the first dose when possible. FAERS hypotension reports frequently note syncope, falls, and fall-related injuries, particularly in elderly patients. The incidence of symptomatic hypotension in the ATLAS trial (high-dose vs. low-dose lisinopril for heart failure, N=3,164) was 11.8% in the high-dose arm (32.5 to 35 mg daily) versus 6.5% in the low-dose arm (2.5 to 5 mg daily) 15.

How FAERS Data Has Shaped Label Revisions

Lisinopril's FDA label has undergone at least 15 revisions since original approval. Several of these were directly prompted by FAERS signal reviews 6.

Key label milestones driven by post-market data:

1992: Angioedema warning strengthened to emphasize airway management requirements and the risk of fatal outcomes.

2003: Hyperkalemia warnings expanded after RALES-era reports showed rising hospitalizations from ACE inhibitor/spironolactone combinations 9.

2006: Pregnancy warning upgraded. First-trimester risk language was added following the Cooper et al. NEJM study 13.

2014: The boxed warning for fetal toxicity was formalized in its current language. Drug interaction sections were updated to include aliskiren (dual RAS blockade contraindicated in diabetic patients) based on ALTITUDE trial findings and FAERS reports of hyperkalemia and renal deterioration with the combination 16.

The FDA Sentinel System (an active surveillance platform analyzing claims data from over 100 million patients) has supplemented FAERS with real-world outcome data for lisinopril, providing denominators that the voluntary FAERS system cannot supply on its own 3.

Lisinopril vs. Other ACE Inhibitors in FAERS

All ACE inhibitors share the same core FAERS signal profile: cough, angioedema, hyperkalemia, AKI, and fetal toxicity. Lisinopril dominates in raw report counts because it is by far the most prescribed member of the class. Adjusted for prescribing volume, the signal magnitudes are comparable across enalapril, ramipril, and lisinopril for most adverse events 7.

One area where lisinopril may differ is in drug interaction complexity. Unlike enalapril (a prodrug requiring hepatic activation) and ramipril (which is also hepatically converted), lisinopril is not metabolized by the liver and has no protein binding. This means fewer pharmacokinetic drug interactions but does not reduce the pharmacodynamic interactions (hyperkalemia, hypotension, AKI) that drive the most serious FAERS signals 6.

The ALLHAT trial remains the largest head-to-head comparison involving lisinopril. At a mean follow-up of 4.9 years, lisinopril showed no significant difference in the primary outcome (fatal coronary heart disease or nonfatal myocardial infarction) compared to chlorthalidone or amlodipine. Heart failure rates were higher in the lisinopril arm compared to chlorthalidone (RR 1.19 to 95% CI 1.07 to 1.31), and stroke rates were higher (RR 1.15 to 95% CI 1.02 to 1.30), particularly in Black participants 5.

Risk Mitigation for Prescribers

Reducing FAERS-reportable events with lisinopril follows established clinical protocols. Check baseline renal function and potassium before starting. Recheck both within 1 to 2 weeks of initiation or dose adjustment. Avoid the "triple whammy" of ACE inhibitor, diuretic, and NSAID without close renal monitoring. Screen for pregnancy in women of reproductive potential. Start at low doses in patients with heart failure, volume depletion, or concurrent diuretic therapy 8.

For angioedema risk, the 2017 ACC/AHA guideline recommends considering ARBs or calcium channel blockers as alternatives in patients with a prior episode of ACE inhibitor angioedema. ARBs carry a much lower angioedema risk (estimated <0.1%), though cross-reactivity is not zero 8.

Dr. Paul Whelton, chair of the 2017 ACC/AHA Hypertension Guideline writing committee, stated: "ACE inhibitors remain a first-line option for hypertension, but prescribers must individualize therapy based on patient characteristics, including race, renal function, and reproductive status" 8.

Patients prescribed lisinopril who develop facial or throat swelling should present to emergency care immediately and never be re-challenged with any ACE inhibitor. Potassium monitoring intervals should be shortened in any patient taking concurrent potassium-elevating medications, with a target serum potassium below 5.0 mEq/L 10.